---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-002613"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:48:02.272023+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte shareholders approve reverse stock split and increase equity plan shares by 2M at annual meeting

## Summary
- Approved reverse stock split at ratio 1:1.1 to 1:100; 5,067,304 for, 2,280,497 against.
- Approved amendment to 2022 Equity Incentive Plan increasing share reserve by 2,000,000 shares.
- Elected five directors (Silverman, Schechter, Abecassis, Weinstein, Walker) to hold office until 2027 annual meeting.
- Ratified CBIZ CPAs P.C. as independent auditor for FY ending April 30, 2026; 6,837,442 for votes.
- Non-binding advisory approval of executive compensation received majority support (3,306,883 for votes).

## SEC filing metadata
- accession: 0001683168-26-002613
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/0001683168-26-002613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-002613
- JSON: https://secwatch.observer/filing/0001683168-26-002613.json
- Plain text: https://secwatch.observer/filing/0001683168-26-002613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.